A European initiative SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) providing the treatment recommendations for the management of CAPS patients has highlighted the dramatically improved outcomes in CAPS patients on the IL-1 blockade (64). The gene discussed is IL1A; the disease is cryopyrin-associated periodic syndrome.